Barley and fatty liver disease have attracted research interest due to barley's nutritional composition, particularly its soluble fibre content called beta-glucan. Non-alcoholic fatty liver disease (NAFLD) affects approximately one in three UK adults, driven largely by obesity, type 2 diabetes, and metabolic syndrome. Whilst barley may form part of a healthy dietary pattern, no UK clinical guideline recommends it as a specific treatment for fatty liver disease. NICE guidance emphasises comprehensive lifestyle modification—sustained energy restriction and increased physical activity—as the cornerstone of NAFLD management. This article examines the evidence for barley's potential role in liver health, its nutritional properties, and practical considerations for safe dietary inclusion.
Summary: No UK clinical guideline recommends barley as a specific treatment for fatty liver disease, though it may form part of a healthy dietary pattern alongside evidence-based lifestyle interventions.
- Barley contains beta-glucan soluble fibre (3–11%) which may improve insulin sensitivity and reduce cholesterol, factors relevant to fatty liver disease pathogenesis.
- Human trials specifically examining barley's direct impact on liver fat content using gold-standard measurements (MRI-PDFF or biopsy) are scarce.
- NICE guidance (NG49) prioritises sustained energy restriction and increased physical activity as primary interventions for non-alcoholic fatty liver disease (NAFLD).
- Barley contains gluten and is strictly contraindicated for individuals with coeliac disease; gradual introduction is recommended to minimise gastrointestinal symptoms.
- FIB-4 score is the first-line non-invasive test for fibrosis risk stratification; Enhanced Liver Fibrosis (ELF) test is used for intermediate or high-risk scores.
- Weight loss of 7–10% is associated with NASH improvement; losses of 10% or more may lead to fibrosis regression in fatty liver disease.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Fatty Liver Disease?
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells—specifically when more than 5% of hepatocytes contain fat, or when MRI-proton density fat fraction (MRI-PDFF) exceeds 5%. This condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), which develops in individuals who consume little to no alcohol, and alcohol-related liver disease (ARLD), directly related to excessive alcohol intake. NAFLD has become increasingly prevalent in the UK, affecting approximately one in three adults, largely driven by rising rates of obesity, type 2 diabetes, and metabolic syndrome. (Note: NAFLD is increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD) in newer literature, though UK NICE guidance currently uses NAFLD.)
In its early stages, fatty liver disease typically produces no symptoms and is often discovered incidentally during abdominal imaging for unrelated conditions. Importantly, liver function tests (LFTs) may be entirely normal in NAFLD, so normal blood results do not exclude the condition. When LFTs are abnormal, elevated liver enzymes (ALT, AST) may prompt further investigation. Some individuals may experience non-specific symptoms including fatigue, malaise, or discomfort in the right upper abdomen. The condition exists on a spectrum: simple steatosis (fat accumulation alone) can progress to non-alcoholic steatohepatitis (NASH), characterised by inflammation and liver cell damage, which may ultimately lead to fibrosis, cirrhosis, and hepatocellular carcinoma.
Risk factors for NAFLD include obesity (particularly central adiposity), insulin resistance, type 2 diabetes mellitus, dyslipidaemia (elevated triglycerides, low HDL cholesterol), hypertension, and metabolic syndrome. According to NICE guidance (NG49), the cornerstone of management involves lifestyle modification, specifically targeting weight reduction through dietary changes and increased physical activity. Weight loss of 7–10% is associated with NASH improvement; losses of 10% or more may lead to fibrosis regression. Early identification and intervention are crucial, as advanced fibrosis substantially increases morbidity and mortality risk.
UK risk stratification and referral pathway: NICE NG49 recommends using the FIB-4 score as a first-line non-invasive test to assess fibrosis risk. A FIB-4 score below 1.3 suggests low risk of advanced fibrosis (in those aged under 65, use a threshold below 2.0 for low risk if aged 65 or over). Scores between 1.3 and 3.25 indicate intermediate risk, and scores above 3.25 suggest high risk. For intermediate or high-risk scores, the Enhanced Liver Fibrosis (ELF) blood test should be performed; an ELF score of 10.51 or above suggests advanced fibrosis and warrants referral to hepatology for specialist assessment. Regular monitoring and management of associated metabolic conditions remain essential.
Seek urgent medical advice (contact your GP, NHS 111, or attend A&E) if you experience: jaundice (yellowing of skin or eyes), abdominal swelling or leg swelling (ascites/oedema), confusion or drowsiness, easy bruising or bleeding, vomiting blood or passing black/tarry stools, severe itching (pruritus), dark urine with pale stools, or unexplained weight loss, as these may indicate advanced liver disease requiring immediate assessment.
Can Barley Help With Fatty Liver?
Barley (Hordeum vulgare) is a cereal grain that has attracted research interest for its potential metabolic benefits, including theoretical effects on liver health. The basis for barley's possible role in fatty liver disease centres on its nutritional composition, particularly its content of soluble fibre, specifically beta-glucan, which comprises 3–11% of the grain depending on variety. Beta-glucan is a viscous, fermentable fibre that influences multiple metabolic pathways relevant to hepatic steatosis. However, it is essential to emphasise at the outset that no UK clinical guideline recommends barley as a treatment for NAFLD, and barley should not be considered a standalone therapeutic intervention.
The proposed mechanisms through which barley may benefit individuals with fatty liver disease are largely hypothesis-generating and extrapolated from broader metabolic research. Firstly, beta-glucan slows gastric emptying and reduces the glycaemic response to meals, potentially improving insulin sensitivity—a key factor in NAFLD pathogenesis. Improved insulin sensitivity may theoretically reduce hepatic de novo lipogenesis (the liver's production of new fat from carbohydrates) and decrease the influx of free fatty acids from adipose tissue. Secondly, soluble fibre binds bile acids in the intestine, promoting their excretion and necessitating increased hepatic conversion of cholesterol to bile acids, thereby potentially reducing circulating cholesterol levels.
Additionally, barley contains various bioactive compounds including phenolic acids, flavonoids, and tocols (vitamin E compounds) that possess antioxidant and anti-inflammatory properties. These may theoretically help mitigate oxidative stress and inflammation—key drivers in the progression from simple steatosis to NASH. Barley also supports beneficial gut microbiota through its prebiotic effects, and emerging evidence suggests the gut-liver axis plays an important role in NAFLD development and progression.
UK regulatory context: Beta-glucans from oats and barley have authorised health claims under retained EU law for reducing blood cholesterol when consumed at a dose of 3 grams per day. Typical servings of barley may or may not reach this threshold without specific product choices. Importantly, no authorised claim exists for beta-glucan in the treatment or prevention of fatty liver disease. Whilst barley may form part of a healthy, energy-restricted dietary pattern (such as a Mediterranean-style diet), it should not be viewed as a targeted therapeutic agent for NAFLD. Clinical benefits for liver fat reduction remain unproven in humans.
Evidence for Barley in Fatty Liver Management
The scientific evidence examining barley's specific effects on fatty liver disease remains limited and predominantly derives from animal studies and small-scale human trials. Several rodent studies have demonstrated that barley or beta-glucan supplementation can reduce hepatic lipid accumulation, improve liver enzyme levels, and decrease markers of oxidative stress and inflammation in diet-induced models of NAFLD. However, extrapolating these findings to human clinical practice requires considerable caution, as animal models do not fully replicate the complex pathophysiology of human fatty liver disease.
Human studies investigating barley's effects on metabolic parameters relevant to NAFLD have shown modest promise. Research has demonstrated that regular consumption of barley or beta-glucan can improve glycaemic control and reduce total and LDL cholesterol—factors that indirectly benefit liver health. Evidence regarding weight loss is inconsistent; whilst barley may aid satiety and support weight management when part of an energy-restricted diet, consistent clinically meaningful weight loss from barley consumption alone is not established. A systematic review of whole grain consumption, including barley, suggested associations with reduced risk of type 2 diabetes and cardiovascular disease, conditions closely linked with NAFLD. However, randomised controlled trials specifically examining barley's direct impact on liver fat content, measured by gold-standard techniques such as MRI-proton density fat fraction (MRI-PDFF) or liver biopsy, are scarce. Without such liver-specific endpoints, definitive conclusions about barley's efficacy in NAFLD cannot be drawn.
The available evidence does not support barley as a specific treatment for fatty liver disease. NICE guidance (NG49) on NAFLD emphasises comprehensive lifestyle modification, prioritising sustained energy (calorie) restriction and increased physical activity as the primary interventions. A balanced diet rich in vegetables, fruits, whole grains (not specifically barley), and lean proteins is recommended. The Mediterranean dietary pattern, which naturally includes whole grains, has the strongest evidence base for improving broader metabolic outcomes relevant to NAFLD. Barley may form part of such a healthy dietary pattern, but should not be viewed as a targeted therapeutic agent. Patients with confirmed or suspected fatty liver disease should receive individualised dietary advice from healthcare professionals or registered dietitians rather than self-prescribing specific foods. Further high-quality, randomised controlled trials with liver-specific endpoints are needed before definitive recommendations can be made regarding barley's role in fatty liver management.
How to Include Barley in Your Diet Safely
For individuals wishing to incorporate barley as part of a balanced diet, several practical considerations ensure safe and beneficial consumption. Barley is available in various forms: pearl barley (outer husk and bran removed, quicker cooking—note that pearl barley is a refined grain, not a wholegrain), pot barley or hulled barley (only outer husk removed, retaining the bran and germ, making it a wholegrain with more fibre and nutrients), and barley flakes (if minimally processed, these retain wholegrain status, similar to rolled oats). Hulled barley and minimally processed barley flakes offer the greatest nutritional benefit. Pearl barley, whilst more processed, remains a nutritious option and is most commonly available in UK supermarkets.
Barley can be incorporated into the diet through multiple preparations. It serves as an excellent addition to soups, stews, and casseroles, providing texture and nutritional value. Cooked barley can be used as a base for salads, mixed with vegetables and lean proteins, or served as a side dish alternative to rice or pasta. Barley flakes can replace oats in porridge, providing variety in breakfast options. A typical serving size is approximately 50–75 g of uncooked barley (yielding 150–200 g cooked), which provides substantial fibre whilst remaining appropriate within a balanced, energy-controlled diet.
Important safety considerations include:
-
Gluten content: Barley contains gluten and is strictly contraindicated for individuals with coeliac disease. People with coeliac disease must avoid all barley (including barley malt extract) unless a food product is certified 'gluten-free' (containing less than 20 parts per million of gluten) and displays the Crossed Grain symbol or equivalent certification. Under UK law (retained EU regulation), 'gluten-free' labelling is legally defined and regulated; however, patients should always check labels carefully. For further guidance, consult Coeliac UK (www.coeliac.org.uk). Wheat allergy does not automatically preclude barley consumption; individuals with wheat allergy should seek individualised advice from an allergist or dietitian, as barley may or may not be tolerated. Non-coeliac gluten sensitivity varies individually; some people may tolerate barley, whilst others may not.
-
Gradual introduction: Increasing fibre intake rapidly can cause gastrointestinal symptoms including bloating, flatulence, and altered bowel habits. Introduce barley gradually, starting with small portions, and ensure adequate fluid intake (approximately 6–8 glasses of water daily, in line with NHS Eatwell guidance).
-
Medication interactions: High-fibre foods may affect the absorption of certain medications. For example, levothyroxine should be taken on an empty stomach, and high-fibre meals should be separated by at least 2–4 hours. If taking regular medications, particularly those with narrow therapeutic windows, consult your GP or pharmacist about appropriate timing of barley consumption relative to medication administration.
-
Energy (calorie) awareness: Whilst nutritious, barley is energy-dense (approximately 350 kcal per 100 g uncooked). For individuals with fatty liver disease aiming for weight reduction, portion control remains essential within an overall energy-restricted dietary plan.
Patients with diagnosed fatty liver disease should discuss dietary modifications with their healthcare team. Seek urgent medical advice (contact your GP, NHS 111, or attend A&E) if you experience: jaundice (yellowing of skin or eyes), abdominal swelling or leg swelling (ascites/oedema), confusion or drowsiness, easy bruising or bleeding, vomiting blood or passing black/tarry stools, severe itching (pruritus), dark urine with pale stools, or unexplained weight loss, as these may indicate disease progression or advanced liver disease requiring immediate assessment. Barley should complement, not replace, evidence-based lifestyle interventions including overall energy restriction, increased physical activity (aim for at least 150 minutes of moderate-intensity exercise weekly, as per UK Chief Medical Officers' guidelines), and management of associated metabolic conditions such as diabetes and dyslipidaemia. Regular monitoring through blood tests (including FIB-4 and, where indicated, ELF) and, if appropriate, imaging or non-invasive fibrosis assessment (such as transient elastography/FibroScan) remains important for tracking disease progression and treatment response.
Reporting side effects: If you experience any suspected side effects from medicines, vaccines, or medical devices, report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or search for 'Yellow Card' in the Google Play or Apple App Store.
Frequently Asked Questions
Does eating barley reduce liver fat in people with fatty liver disease?
Human trials specifically measuring barley's direct effect on liver fat content using gold-standard techniques (MRI-PDFF or liver biopsy) are scarce, so definitive conclusions cannot be drawn. Barley may form part of a healthy dietary pattern that supports metabolic health, but it should not be viewed as a targeted therapeutic agent for fatty liver disease.
How much barley should I eat daily to help with fatty liver?
No specific daily amount of barley is recommended for fatty liver disease, as barley is not an established treatment. A typical serving of 50–75 g uncooked barley (150–200 g cooked) provides substantial fibre and can be incorporated into a balanced, energy-controlled diet as part of comprehensive lifestyle modification.
Can I eat barley if I have coeliac disease and fatty liver?
No, barley contains gluten and is strictly contraindicated for individuals with coeliac disease. People with coeliac disease must avoid all barley products unless certified 'gluten-free' (containing less than 20 parts per million of gluten) and displaying the Crossed Grain symbol or equivalent certification.
What is the difference between barley and oats for liver health?
Both barley and oats contain beta-glucan soluble fibre with authorised UK health claims for reducing blood cholesterol when consumed at 3 grams daily. Neither has specific evidence or authorised claims for treating fatty liver disease, though both may form part of a healthy dietary pattern supporting metabolic health.
Is pearl barley or hulled barley better for fatty liver disease?
Hulled barley (pot barley) retains the bran and germ, making it a wholegrain with more fibre, nutrients, and beta-glucan than pearl barley, which is refined. For general health benefits, hulled barley offers greater nutritional value, though neither is specifically recommended as a treatment for fatty liver disease.
What lifestyle changes actually work for reversing fatty liver?
NICE guidance recommends sustained energy (calorie) restriction and increased physical activity as primary interventions for fatty liver disease. Weight loss of 7–10% is associated with NASH improvement, and losses of 10% or more may lead to fibrosis regression, alongside management of associated conditions like diabetes and dyslipidaemia.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
